Isatin Bis-Imidathiazole Hybrids Identified as FtsZ Inhibitors with On-Target Activity Against Staphylococcus aureus

Area of Science:

• Medicinal Chemistry
• Microbiology
• Computational Chemistry

Background:

• Antimicrobial resistance is a growing global health threat, necessitating the development of novel therapeutic agents.
• Isatin derivatives are known for diverse biological activities, but their potential as antimicrobial agents targeting specific bacterial mechanisms requires further exploration.

Purpose of the Study:

• To design, synthesize, and evaluate novel isatin bis-imidathiazole hybrids for enhanced antimicrobial properties.
• To investigate the anti-biofilm and anti-methicillin-resistant Staphylococcus aureus (MRSA) potential of the synthesized compounds.
• To elucidate the molecular mechanism of action and identify key structural features contributing to antibacterial efficacy.

Main Methods:

• Synthesis of a series of isatin bis-imidathiazole hybrids.
• In vitro antimicrobial activity testing against various pathogens, including Staphylococcus aureus and MRSA.
• Cytotoxicity assays using epithelial cells and human red blood cells.
• Anti-biofilm assays.
• Structure-activity relationship (SAR) analysis.
• Molecular docking and molecular dynamics (MD) simulations to identify the target protein and binding mode.

Main Results:

• Several synthesized isatin bis-imidathiazole hybrids exhibited significant inhibitory activity against Staphylococcus aureus (13.8–90.1 µM) without exhibiting toxicity to host cells.
• The most potent derivative demonstrated efficacy against MRSA and possessed anti-biofilm properties.
• SAR studies identified crucial structural elements for antibacterial activity.
• Molecular modeling revealed that the active compounds inhibit the polymerization of FtsZ, a vital protein in bacterial cell division.

Conclusions:

• The designed isatin bis-imidathiazole hybrids represent a promising new class of antimicrobial agents.
• Targeting bacterial FtsZ polymerization is a viable strategy for developing novel antibacterial drugs.
• These findings provide a foundation for the rational design of more potent and broader-spectrum isatin-based FtsZ inhibitors for combating bacterial infections.